ITD Study (AMaRC 16-02)

A prospective, multi-centre, single arm, phase 2 assessment of the efficacy and safety of the combination of ixazomib, thalidomide and dexamethasone (ITD) for relapsed and/or refractory multiple myeloma after 1 to 3 prior lines of therapy.

The primary purpose of this trial is to evaluate the safety and efficacy of a combination of ixazomib, thalidomide and dexamethasone (ITD) for the treatment of multiple myeloma which has progressed despite one to three lines of previous therapy.

More information available at: http://www.amarconline.org/clinical-trials/itd

Project Information

Institution:

Australasian Myeloma Research Consortium (AMaRC C/- Alfred Health)

Specialities:

Haematology

Other (specify below)

Oncology

End date:

Suitability:

Parts of research done:

Literature review, Research proposal, Ethics approval, Data collection, Data analysis

Positions Available:

Researchers

Data Collector

Statistician

Current Funding:

Website

  • Twitter

Contact

Andrew Spencer

Please fill out the form below to express your interest in this research project. It is free to contact a project owner and express interest in a project. We recommend writing a detailed message regarding why you are interested in the project (e.g. what skills you can bring to the team) or what information you are seeking (e.g. detail regarding the study duration). All information you provide will be shared with the primary researcher, including your contact details. Thank you for your interest in this project.

LINKS:

ABOUT:

Melbourne,

VIC. 3002

Australia

 

0424 730 627

info@theresearchcollab.com

ABN: 77 640 321 295

CONNECT WITH US:

  • Twitter
  • White Facebook Icon
  • White Instagram Icon
  • LinkedIn - White Circle